A phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous Non- Small Cell Lung Cancer with brain metastasis and Harboring Epidermal Growth Factor Receptor Mutations.
Phase 2
- Conditions
- on-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000012514
- Lead Sponsor
- Department of Respiratory Medicine, Kumamoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1)Squamous cell carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 3)History of EGFR-TKI, VEGF antibody allergic reaction. 4)Brain metastasis expected bleeding 5)Radiotherapy enforcement example for the brain 6)Active severe comorbidity disease. 7)History of hemoptysis 8)Uncontrollable hypertension 9)History of gastrointenstinal perforation or diverticulitis or fistula 10)Scheduled operation 11)Active concomitant malignancy 12)Pregnant or breast-feeding females 13)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method